← Organizations
Sponsor / Institution
Mayo Clinic
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
2
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
0 / 2
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
85
Completion Signal
50
Programs by Stage
Phase 21
Phase 31
Trial / Program Status
Active2
Modality Mix
Behavioral/Rehabilitation1
Small Molecule1
Indication Coverage
Hearing Loss2
Age-Related Hearing Loss1
Aminoglycoside-Induced Hearing Loss1
Ototoxicity1
Program Types
Procedure/Rehab1
Therapeutic1
Population Tags
adult1
age-related1
amikacin1
cognitive-health1
hearing-aid-user1
ntm1
older-adult1
ototoxicity1
rehabilitation1
sensorineural1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksOHSU/Oricula ORC-13661 amikacin otoprotection study
Details checked
Small MoleculePhase 2Active
Oral ORC-13661 small molecule evaluated in a randomized Phase 2 dose-ranging trial to prevent or mitigate IV amikacin-associated ototoxic hearing loss in adults with nontuberculous mycobacterial disease.
Data checks: investigator-led-study, industry-collaborator-involved
ACHIEVE brain-health hearing intervention follow-up study
Details checked
Behavioral/RehabilitationPhase 3Active
Active-not-recruiting Phase 3 follow-up to ACHIEVE evaluating long-term effects of best-practice hearing rehabilitation, including hearing aids and individualized audiology sessions, on cognitive decline and brain-health outcomes in older adults.
Data checks: institution-led-study, federal-sponsor